An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a).

MLA

Caparrós-Martín, Jose A., et al. “An Analysis of the Gut Microbiota and Related Metabolites Following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(A).” Microorganisms, vol. 12, no. 1, Jan. 2024. EBSCOhost, https://doi.org/10.3390/microorganisms12010170.

APA

Caparrós-Martín, J. A., Maher, P., Ward, N. C., Saladié, M., Agudelo-Romero, P., Stick, S. M., Chan, D. C., Watts, G. F., & O’Gara, F. (2024). An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a). Microorganisms, 12(1). https://doi.org/10.3390/microorganisms12010170

Chicago

Caparrós-Martín, Jose A, Patrice Maher, Natalie C Ward, Montserrat Saladié, Patricia Agudelo-Romero, Stephen M Stick, Dick C Chan, Gerald F Watts, and Fergal O’Gara. 2024. “An Analysis of the Gut Microbiota and Related Metabolites Following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(A).” Microorganisms 12 (1). doi:10.3390/microorganisms12010170.